Production and Immunogenicity of Multiple Antigenic Peptide (MAP) Constructs Derived from the S1 Glycoprotein of Infectious Bronchitis Virus (IBV)
Synthetic peptides were prepared as multiple antigenic peptide (MAP) constructs to the S1 glycoprotein of infectious bronchitis virus (IBV). The MAP system has been used in the production of anti-peptide and anti-protein antibodies. It has an advantage over linking peptides to a highly immunogenic carrier molecule because antibodies are not produced to the MAP core matrix of lysine residues. Two 25-residue peptides were synthesized to the Arkansas serotype and two were synthesized to the Massachusetts serotype of IBV. The peptide sequences correspond to amino acid residues 64 to 88 and to residues 117 to 141 for each of the IBV serotypes. A MAP construct for each peptide was prepared by linking 4 copies of a peptide to the immunogenetically inert core matrix of lysine residues. The MAP constructs were used to immunize specific pathogen free chickens. Anti-peptide ELISA titers and the dot immunobinding assay against the homologous peptide were positive for all of the sera tested whereas the anti-whole virus ELISA titers and virus neutralization titers were negative for all of the sera tested. Hyperimmune sera against whole virus did not cross react with synthetic peptides made to the heterologous virus suggesting a possible role for the MAP constructs in a serotype specific dot blot or ELISA test for IBV.
KeywordsSynthetic Peptide Infectious Bronchitis Virus Multiple Antigenic Peptide ELISA Titer Core Matrix
Unable to display preview. Download preview PDF.
- 1.Murphy, B. R., and Chanock, R. M. Immunization against viruses. In Fields, B. N., and Knipe, D. M. (eds). Virology. 2nd ed. Raven Press, Ltd., New York. 1990 pp. 469–502.Google Scholar
- 2.Langeveld, J. P. M., Casal, J. I., Osterhaus, A. D. M. E., Cortes, E., de Swart, R., Vela, C., Dalsgaard, K., Puijk, W. C., Schaaper, W. M. M., and Meloen, R. H. First peptide vaccine providing prptection against viral infection in the target animal: Studies of canine parvovirus in dogs. J. of Virol. 1994;68:4506–4513.Google Scholar
- 3.Koolen, M. J. M., Borst, M. A. J., Horzinek, M. C., and Spaan, W. J. M. Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J. of Virol. 1990;64:6270–6273.Google Scholar
- 4.Talbot, P. J., Dionne, G., and Lacroix, M. Vaccination against lethal coronavirus-induced encephalitis with a synthetic decapeptide homologous to a domain in the predicted peplomer stalk. J. of Virol. 1988;62:3032–3036.Google Scholar
- 5.Daniel, C., Lacroix, M., Talbot, P. J. Mapping of linear antigenic sites on the S glycoprotein of a neurotropic murine coronavirus with synthetic peptides: A combination of nine prediction algorithms fails to identify relevant epitopes and peptide immunogenicity is drastically influenced by the nature of protein carrier. Virology. 1994;202:540–549.PubMedCrossRefGoogle Scholar
- 8.van Regenmortel, M. H. V., Briand, J. P., Muller, S. and Plaue, S. Synthetic polypeptides as antigens. In: Burdon, R. H. and van Knippenberg, P. H. (eds). Laboratory techniques in biochemistry and molecular biology, vol. 19. Elsevier, Amsterdam 1988. pp 1–75, 131–191.Google Scholar
- 11.Sambrook, J., Fritsch, E. F., Maniatis, T. Molecular Cloning A laboratory Manual. Cold Spring Harbor Laboratory Press, New York. 1989, pp. 18.60–18.65.Google Scholar
- 12.Serine, D. A. Virus propagation in embryonating eggs. In Purchase, H. G., Arp, L. H., Domermuth, C. H., Pearson, J. E. (eds). A Laboratory Manual for the Isolation and Identification of Avian Pathogens. 3rd ed. The American Association of Avian Pathologists, Kennett Square. 1989, pp. 176–181.Google Scholar
- 13.Livingstone, A. Epitopes. In Roitt, I. M, Delves, P. J. (eds). Encyclopedia of Immunology. Academic Press, San Diego. 1992 pp. 515–517.Google Scholar